Australia's largest stock trading and investment forum Australia's #1 stock forum

AKE

0.00%

$9.83 allkem limited

Merger: Yes or No, page-473

First 473 Last

Share
Profile

Follow
Celestine8

187 Posts.

40

27/11/23

12:51

Post #: 71124514
Share

Originally posted by akgo01: ↑

From this chart above, we can see that Lithium Carbonate price started climbing up in early 2021.

Then I wanted to see the performance of the share prices of Albemarle, Livent, Allkem, and Pilbara starting early 2021. So I got the chart below:

I couldn't believe what I saw. I thought there was something wrong; surely Albemarle and Livent couldn't be that bad compared to Allkem or/and Pilbara.

So I got the chart below comparing Albemarle with Livent only:

The result is the same. After 3 years, the share prices of Albemarle and Livent have made a negative growth, while Allkem has made 110% growth and Pilbara 435% growth. Is this right? I really find it hard to believe. But graphs don't lie, do they?

Wow! Here we have the undeniable evidence (if not proof) that being listed in NYSE has no advantage at all. If anything the evidence shows a big disadvantage; that it is much more volatile for being listed in NYSE. That is probably just as expected considering most institutions who short sell are based in the US.

So this evidence stands as a reminder to those of you who will vote Yes to the merger, that you have to be ready to have a much higher level of volatility with the NewCo shares being listed in NYSE.

(On top of that, there is an added volatility with the exchange rate!)

It is just something to think about before making that crucial decision.

Expand

Excellent work akg. Thank you

AKE Price at posting: $8.38 Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 593 more messages in this thread...

First 473 Last

Add AKE (ASX) to my watchlist

Merger: Yes or No, page-473

Top Stories

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Zeta Resources seeks to resolve the Panoramic takeover story

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News